Highlights

  • Nuchev Ltd shares fell 6.67% to AUD 0.14 on 27 April 2026 following the release of its Q3 FY26 Appendix 4C update.
  • Group sales revenue declined 11% quarter-on-quarter and 12% year-on-year to AUD 4.7 million.
  • Year-to-date Group revenue stood at AUD 16.5 million as at 31 March 2026.
  • Net cash used in operating activities was AUD 2.9 million for the quarter.
  • Cash balance closed at AUD 2.1 million, supported by working capital facility usage and disciplined cash management.

Nuchev Ltd (ASX: NUC) shares came under pressure, sliding 6.67% to AUD 0.14 during the 27 April 2026 trading session after the company released its Appendix 4C quarterly cash flow and activity report for the period ended 31 March 2026 (Q3 FY26). The decline followed a softer operational update, with investors reacting to lower group sales revenue, negative operating cash flow, and continued volatility across key business segments.

Despite the weakness in today’s session, the stock remains 22.22% lower over the past year, reflecting ongoing challenges in achieving consistent revenue conversion across domestic and international channels.

Revenue Decline Across Key Channels Weighs on Quarterly Performance

For Q3 FY26, Nuchev reported Group sales revenue of AUD 4.7 million, representing a decline of 11% quarter-on-quarter and 12% compared to the prior corresponding period. Year-to-date revenue for the nine-month period stood at AUD 16.5 million as of 31 March 2026.

The company noted that trading conditions during the quarter were mixed across its operating segments. While ANZ retail performance remained comparatively resilient, international revenue conversion continued to be impacted by timing-related factors, including shipment scheduling, regulatory approvals in export markets, and customer ordering cycles. The practitioner channel also remained softer overall, although some stabilisation was observed toward the end of the quarter.

This uneven performance across segments contributed to the overall decline in reported revenue for the period.

Oli6 Nutritionals Remains Core Revenue Driver but Records Decline

The Oli6® Nutritionals segment, which remains the company’s primary revenue contributor, generated AUD 3.2 million in Q3 FY26 sales. This represented a decline of 21% quarter-on-quarter and 8% year-on-year.

Despite the decline, domestic retail channels continued to provide relative stability, supported by ongoing engagement across grocery and pharmacy partners. Performance in this segment was also influenced by stronger prior-period ordering patterns, including pipeline fill effects following earlier out-of-stock recovery periods.

The company highlighted that retail scan data continued to reflect underlying brand presence in the domestic market, even as quarterly revenue softened compared to earlier periods.

International and Practitioner Segments Continue to Show Timing Volatility

International markets remained inconsistent during Q3 FY26, with revenue conversion affected primarily by timing-related issues rather than a structural change in demand conditions. Shipment delays, regulatory processes in key export regions, and variability in customer ordering patterns all contributed to uneven quarterly performance.

Management noted that efforts are ongoing with distribution partners to improve market readiness, replenishment planning, and execution across export channels.

In the practitioner channel, revenue totalled AUD 1.5 million, reflecting an increase of 17% quarter-on-quarter but a decline of 20% year-on-year. Trading conditions remained subdued, although the company reported stabilisation toward the end of the quarter. Efforts continue to focus on distributor relationships, pricing frameworks, and route-to-market execution to support more consistent performance.

Cash Flow Position Reflects Continued Working Capital Pressure

Nuchev reported net cash used in operating activities of AUD 2.9 million for Q3 FY26. This outflow was driven by timing differences between customer receipts and supplier payments, alongside continued investment in inventory and product development initiatives.

Customer receipts during the quarter amounted to AUD 4.2 million, while payments related to manufacturing, operating costs, staffing, and administration contributed to overall cash usage.

Cash and cash equivalents at the end of the quarter stood at AUD 2.1 million. The company also noted the use of an unsecured working capital facility of AUD 2.0 million, which supports short-term liquidity requirements.

Management emphasised that cash flows are influenced by seasonality, inventory build cycles, and the timing of customer receipts, which can result in quarter-to-quarter variability.

Strategic Focus on Portfolio Expansion and Channel Execution

During the quarter, Nuchev continued to progress its broader strategic initiatives across retail, practitioner, and distribution channels. The company highlighted ongoing investment in new product development (NPD), which remains a key component of its long-term growth strategy.

NPD efforts during the period were directed toward category expansion and portfolio diversification across both consumer and practitioner segments, with additional product initiatives aimed at supporting future revenue streams.

The company also advanced its distribution agreement structure following the transition involving Brauer, Skin Physics, and Rapid Loss brands. Under this arrangement, Nuchev assumes a broader commercial role, with expectations of improved margin capture and greater operational leverage as volumes scale, although this also increases working capital requirements.

Management Commentary Highlights Focus on Discipline and Path to Profitability

Nuchev CEO Nathan Cheong described Q3 FY26 as a “mixed quarter,” noting relative resilience in domestic retail performance but continued challenges in international conversion and practitioner channel consistency.

He highlighted that while retail execution in Australia remained supportive of brand stability, variability in international shipments and distributor-related disruptions impacted overall performance. The practitioner channel also required further work to stabilise trading conditions.

Importantly, management reiterated that the business continues to focus on disciplined execution, working capital management, and progressing toward break-even and profitability over the short to medium term.

Financial Position and Funding Considerations

The company’s cash position of AUD 2.1 million reflects ongoing investment in inventory and product development, alongside operational cash outflows. During the quarter, Nuchev also transitioned to a new AUD 2.0 million unsecured working capital facility to support liquidity requirements.

The report indicates that available funding is influenced by both cash reserves and undrawn facilities, with liquidity management remaining a key operational focus.

Management continues to assess additional funding options as required, while also engaging with major shareholders regarding potential support to strengthen the balance sheet position.

What This Means for Investors

The Q3 FY26 update highlights continued pressure on Nuchev’s revenue base, with declines across group sales and segment-level volatility weighing on overall performance. While domestic retail demand showed relative stability, international and practitioner channels remained inconsistent, affecting revenue conversion.

At the same time, negative operating cash flow and a low cash balance underscore the importance of near-term liquidity management. However, ongoing product development initiatives, distribution expansion efforts, and channel restructuring indicate that the company is continuing to position itself for longer-term operational improvement.

Investors are likely to remain focused on whether management can stabilise revenue trends, improve cash conversion, and progress toward profitability in upcoming quarters.